Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Schellekens

Showing results (1-10 of 155) with videos related to

Pageof 16
Sort By:
Drug Discovery Today|May 12, 2009
Assessing the bioequivalence of biosimilars The Retacrit caseH Schellekens
Journal of Nephrology|July 25, 2008
Recombinant human erythropoietins, biosimilars and immunogenicityH Schellekens
Lancet (London, England)|July 16, 1999
Health risks of genetically modified foodsH Schellekens
Experientia|June 15, 1989
Animal models in interferon research: some current trendsH Schellekens
Trends in Biotechnology|July 31, 2004
When biotech proteins go off-patentH Schellekens
European Journal of Clinical Investigation|December 21, 2004
Biosimilar therapeutic agents: issues with bioequivalence and immunogenicityH Schellekens
Tijdschrift Voor Diergeneeskunde|February 23, 2002
[Genetic modification of animals]H Schellekens
Nature|September 19, 1996
Spending on BSE researchH Schellekens
Biotherapy (Dordrecht, Netherlands)|January 1, 1988
Between clones and clinicH Schellekens
The International Journal of Risk & Safety in Medicine|June 16, 2011
The sponsored pandemic of the Mexican flu?D Bijl, H Schellekens
Pageof 16

Showing results (1-10 of 155) with videos related to

Sort By:
Pageof 16
Drug Discovery Today|May 12, 2009
Assessing the bioequivalence of biosimilars The Retacrit caseH Schellekens
Journal of Nephrology|July 25, 2008
Recombinant human erythropoietins, biosimilars and immunogenicityH Schellekens
Lancet (London, England)|July 16, 1999
Health risks of genetically modified foodsH Schellekens
Experientia|June 15, 1989
Animal models in interferon research: some current trendsH Schellekens
Trends in Biotechnology|July 31, 2004
When biotech proteins go off-patentH Schellekens
European Journal of Clinical Investigation|December 21, 2004
Biosimilar therapeutic agents: issues with bioequivalence and immunogenicityH Schellekens
Tijdschrift Voor Diergeneeskunde|February 23, 2002
[Genetic modification of animals]H Schellekens
Nature|September 19, 1996
Spending on BSE researchH Schellekens
Biotherapy (Dordrecht, Netherlands)|January 1, 1988
Between clones and clinicH Schellekens
The International Journal of Risk & Safety in Medicine|June 16, 2011
The sponsored pandemic of the Mexican flu?D Bijl, H Schellekens
Pageof 16